EVOLUS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.93 USD | +2.54% |
|
+3.36% | +22.79% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 263M 20.6B | Sales 2025 * | 348M 27.33B | Capitalization | 810M 63.53B |
|---|---|---|---|---|---|
| Net income 2024 * | -43M -3.37B | Net income 2025 * | -12M -942M | EV / Sales 2024 * | 3.22 x |
| Net Debt 2024 * | 36M 2.83B | Net Debt 2025 * | 46M 3.61B | EV / Sales 2025 * | 2.46 x |
| P/E ratio 2024 * |
-19
x | P/E ratio 2025 * |
-65.2
x | Employees | 279 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on Evolus, Inc.
More recommendations
More press releases
| 1 day | +2.54% | ||
| 1 week | +3.36% | ||
| 1 month | -2.19% | ||
| 3 months | -13.28% | ||
| 6 months | +32.62% | ||
| Current year | +22.79% |
1 week
12.34
13.00
1 month
12.3413.82
Current year
9.8015.43
1 year
7.0715.43
3 years
5.0615.43
5 years
2.8520.27
10 years
2.8539.50
| Managers | Title | Age | Since |
|---|---|---|---|
David Moatazedi
CEO | Chief Executive Officer | 46 | 05/05/18 |
Sandra Beaver
DFI | Director of Finance/CFO | 46 | 04/09/22 |
Rui Avelar
CTO | Chief Tech/Sci/R&D Officer | 62 | 31/12/13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Gill
BRD | Director/Board Member | 69 | 11/02/18 |
Simone Blank
BRD | Director/Board Member | 61 | 31/12/17 |
Robert Hayman
BRD | Director/Board Member | 65 | 31/12/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 1,487 M€ | +7.77% | - | |
| 0.00% | 9 M€ | +9.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/05/24 | 12.93 | +2.54% | 425,086 |
| 30/05/24 | 12.61 | -0.24% | 237,230 |
| 29/05/24 | 12.64 | +0.08% | 266,926 |
| 28/05/24 | 12.63 | +0.96% | 419,510 |
Delayed Quote Nasdaq, May 31, 2024 at 09:00 pm
More quotes
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
Sector
Pharmaceuticals
Calendar
06/06/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
12.93
USD
Average target price
22.29
USD
Spread / Average Target
+72.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.79% | 810M | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- EOLS Stock